Get the Stockscreener App
2.3672
3.37%
0.0772
Cumberland Pharmaceuticals Inc stock is traded at $2.3672, with a volume of 11,814.
It is up +3.37% in the last 24 hours and up +91.68% over the past month.
Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The Company has one operating segment which is specialty pharmaceutical products. The company's primary target markets are hospital acute care, gastroenterology, rheumatology, and oncology. The company promotes its approved products through its hospital, field, and oncology sales divisions in the United States and establishes a network of international partners to register and provide medicines to patients in their countries. The company's revenue is derived from the product sales of FDA-approved pharmaceutical brands. Its brands include Acetadote, Caldolor, Kristalose, Omeclamox, Sancuso, Vaprisol and Vibativ.
See More
Previous Close:
$2.29
Open:
$2.35
24h Volume:
11,814
Relative Volume:
0.01
Market Cap:
$31.88M
Revenue:
$37.79M
Net Income/Loss:
$-10.38M
P/E Ratio:
-3.2427
EPS:
-0.73
Net Cash Flow:
$-1.00M
1W Performance:
-0.12%
1M Performance:
+91.68%
6M Performance:
+61.58%
1Y Performance:
+5.68%
1-Day Range:
$2.262
$2.38
1-Week Range:
$2.18
$2.44
52-Week Range:
$1.04
$3.05
Cumberland Pharmaceuticals Inc Stock (CPIX) Company Profile
Name
Cumberland Pharmaceuticals Inc
Sector
Phone
615-255-0068
Address
2525 WEST END AVENUE, NASHVILLE,, TN
Compare CPIX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CPIX
Cumberland Pharmaceuticals Inc
|
2.38 | 31.88M | 37.79M | -10.38M | -1.00M | -0.73 |
|
ZTS
Zoetis Inc
|
162.22 | 74.31B | 9.15B | 2.43B | 2.31B | 5.32 |
|
HLN
Haleon Plc Adr
|
9.495 | 42.98B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.38 | 42.51B | 30.27B | 1.93B | 3.45B | 0.6044 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
21.61 | 24.56B | 16.77B | -959.00M | 1.37B | -0.85 |
|
VTRS
Viatris Inc
|
12.04 | 14.33B | 15.05B | -883.30M | 1.89B | -0.74 |
Cumberland Pharmaceuticals Inc Stock (CPIX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-12-12 | Reiterated | UBS | Neutral |
| Feb-01-11 | Reiterated | UBS | Neutral |
| Dec-16-10 | Downgrade | UBS | Buy → Neutral |
| Aug-17-10 | Downgrade | Jefferies | Buy → Hold |
| Aug-17-10 | Reiterated | Morgan Joseph | Buy |
| Aug-17-10 | Reiterated | UBS | Buy |
| May-14-10 | Reiterated | Morgan Joseph | Buy |
View All
Cumberland Pharmaceuticals Inc Stock (CPIX) Latest News
Cumberland Pharmaceuticals (NASDAQ:CPIX) Coverage Initiated at StockNews.com - Defense World
Cumberland Pharmaceuticals director James Jones acquires $1,317 in stock By Investing.com - Investing.com Nigeria
Cumberland Pharmaceuticals CEO AJ Kazimi purchases $1317 in stock By Investing.com - Investing.com Nigeria
Cumberland Pharmaceuticals director Krogulski buys $8,209 in stock By Investing.com - Investing.com Canada
Cumberland Pharmaceuticals director Caroline Young acquires $256 in stock By Investing.com - Investing.com Canada
Cumberland Pharmaceuticals director Krogulski buys $8,209 in stock - Investing.com
Cumberland Pharmaceuticals director James Jones acquires $1,317 in stock - Investing.com India
Cumberland Pharmaceuticals CEO AJ Kazimi purchases $1317 in stock - Investing.com
Cumberland Pharmaceuticals (NASDAQ:CPIX) Now Covered by StockNews.com - Defense World
Athira Pharma (NASDAQ:ATHA) Stock Quotes, Forecast and News Summary - Benzinga
StockNews.com Begins Coverage on Cumberland Pharmaceuticals (NASDAQ:CPIX) - Defense World
Cumberland Pharmaceuticals (NASDAQ:CPIX) Share Price Crosses Above 200-Day Moving Average – Here’s Why - Defense World
StockNews.com Initiates Coverage on Cumberland Pharmaceuticals (NASDAQ:CPIX) - Defense World
FDA APPROVES ACETADOTE® sNDA - Citizentribune
3 Promising Penny Stocks With Market Caps Under $2B In US - Simply Wall St
Cumberland Pharmaceuticals stock pops - Nashville Post
Cumberland Stock Soars 90% After FDA Approval for Acetadote Dosing Change - GuruFocus.com
Stock Skyrockets! Discover What’s Fueling This Company’s Massive Surge. - elblog.pl
Gold Gains Over 1%; Ollie's Bargain Outlet Shares Jump After Q3 Earnings - Benzinga
Why Is Cumberland Pharmaceuticals Stock Trading Over 100% on Tuesday? - Benzinga
Cumberland Pharma Stock Hits 16-Month High After FDA Approves Liver Drug Regimen: Retail’s Thrilled - MSN
Cumberland (CPIX) Celebrates FDA Nod With Market Rally - Stocks Telegraph
FDA Approves Simplified Dosing For Cumberland's Acetadote - Contract Pharma
CPIX stock touches 52-week high at $2.92 amid market fluctuations - Investing.com
Cumberland Pharma Shares Rise 56% After FDA Approves Liver Drug Acetadote - MarketWatch
Cumberland Pharma Secures FDA Approval for Breakthrough Acetadote Dosing Innovation - StockTitan
Cumberland Pharmaceuticals director James Jones buys $1,754 in stock By Investing.com - Investing.com South Africa
Cumberland Pharmaceuticals CEO A.J. Kazimi buys $1,754 in stock - Investing.com India
Cumberland Pharmaceuticals director Caroline Young buys $755 in stock By Investing.com - Investing.com Nigeria
Cumberland Pharmaceuticals director Caroline Young buys $755 in stock - Investing.com
Cumberland Pharmaceuticals director James Jones buys $1,754 in stock - Investing.com
Cumberland Pharmaceuticals director Kenneth Krogulski buys $9,347 in stock - Investing.com
Cumberland Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 - Marketscreener.com
Cumberland Pharmaceuticals (NASDAQ:CPIX) Now Covered by Analysts at StockNews.com - Defense World
Cumberland Pharma stock hits 52-week low at $1.04 By Investing.com - Investing.com South Africa
Cumberland Pharma stock hits 52-week low at $1.04 - Investing.com
Newly Released Insights in to the Artificial Saliva Market Insights - WhaTech
Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Q3 2024 Earnings Call Transcript - MSN
Corneal Ulcer Treatment Market 2034: Clinical Trials, Medication, Prevalence, Incidence, Therapies, EMA, PDMA, FDA Approvals, and Companies by DelveInsight - The Globe and Mail
Ibuprofen Injection Shows Better Real-World Outcomes in Comparative Study - Pharmacy Practice News
Cumberland Pharma stock hits 52-week low at $1.07 - Investing.com
Cumberland Pharma stock hits 52-week low at $1.07 By Investing.com - Investing.com UK
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Purchased by Cumberland Partners Ltd - MarketBeat
Ibuprofen injection exhibits kidney safety with cost benefits over ketorolac: Study - Medical Dialogues
Cumberland Pharmaceuticals Third Quarter 2024 Earnings: US$0.11 loss per share (vs US$0.073 loss in 3Q 2023) - Yahoo Canada Finance
Cumberland Pharmaceuticals Inc. (CPIX) Quarterly 10-Q Report - Quartzy
Cumberland Pharmaceuticals Inc (CPIX) Q3 2024 Earnings Call Highlights: Navigating Challenges ... By GuruFocus - Investing.com Canada
FDA Grants Orphan Drug Designation to Ifetroban for Treatment of Duchenne Muscular Dystrophy-Associated Cardiomyopathy - Pharmacy Times
Cumberland: Q3 Earnings Snapshot - mySA
Cumberland Pharmaceuticals Reports Q3 2024 Earnings and Developments - TipRanks
Cumberland Pharmaceuticals Inc Stock (CPIX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.01%
0.93%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):